The effect of resveratrol on metabolism and cardiovascular risk profile in patients with chronic obstructive pulmonary disease (COPD)

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 23

Inclusion Criteria

- COPD (GOLD I-IV);
- Current or ex-smoker;
- Age >18 years.

Exclusion Criteria

- COPD patients planned for pulmonary rehabilitation or who recently participated in a rehabilitation program in the previous 6 months;
- Investigator*s uncertainty about willingness or ability of the patient to comply with the protocol requirements;
- Participation in any other study involving investigational exercise training, nutritional or pharmacological intervention;
- Oral glucocorticoid use;
- Recent exacerbation (<4 weeks) that required oral steroids and/or hospital admission;
- Subject is pregnant, planning to be pregnant during the study period, lactating, or women who consider themselves to be of childbearing potential and who are engaged in an active sex life and are unwilling to commit to the use of an approved form of contraception throughout the study period. The method of contraception must be recorded in the source documentation;
- Diabetes mellitus (type 1 and 2);
- Active cardiovascular disease or a cardiovascular event (such as myocardial infarction, cerebrovascular haemorrhage/infarction) in the previous 6 months;
- Recent major surgery;
- Thyroid dysfunction, current hepatic or renal disorders;
- Current malignancy (except for dermal malignancies);
- Central or obstructive sleep apnea;
- Current alcohol consumption > 20 grams alcohol/day;
- Intake of resveratrol containing dietary supplements;

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary outcome of this study is:<br /><br>High sensitivity systemic inflammation (CRP) as a clinical marker of systemic<br /><br>inflammation via blood sampling.</p><br>

Secondary Outcome Measures